

Carlo Genova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8947962/publications.pdf>

Version: 2024-02-01

94
papers

2,965
citations

185998

28
h-index

205818

48
g-index

96
all docs

96
docs citations

96
times ranked

5401
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. <i>Lancet Oncology</i> , The, 2020, 21, 914-922.	5.1	503
2	Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 479-485.	1.2	253
3	The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients. <i>Journal of Translational Medicine</i> , 2019, 17, 74.	1.8	103
4	Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges. <i>Cancers</i> , 2020, 12, 17.	1.7	82
5	Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. , 2021, 9, e002421.		80
6	Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade. <i>Frontiers in Immunology</i> , 2021, 12, 799455.	2.2	76
7	Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients. <i>Oncologist</i> , 2018, 23, 936-942.	1.9	69
8	Clinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch System. <i>Frontiers in Oncology</i> , 2014, 4, 242.	1.3	63
9	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of $\geq 50\%$. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2209-2221.	2.0	60
10	Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression $\geq 50\%$: a multicenter study with external validation. , 2020, 8, e001403.		57
11	Radiomic Detection of EGFR Mutations in NSCLC. <i>Cancer Research</i> , 2021, 81, 724-731.	0.4	57
12	Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer. <i>European Journal of Cancer</i> , 2019, 123, 72-80.	1.3	54
13	Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 125.	2.2	53
14	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 50\%$ and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , 2020, 21, 498-508.e2.	1.1	50
15	Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab. <i>Journal of Clinical Medicine</i> , 2019, 8, 1011.	1.0	45
16	Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non-small Cell Lung Cancer: ^{18}F -FDG PET/CT Study. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1764-1769.	2.8	44
17	Comparison Between ^{18}F -FDG PET-Based and CT-Based Criteria in Non-small Cell Lung Cancer Patients Treated with Nivolumab. <i>Journal of Nuclear Medicine</i> , 2020, 61, 990-998.	2.8	44
18	Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient. <i>Cancers</i> , 2020, 12, 1125.	1.7	43

#	ARTICLE	IF	CITATIONS
19	Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations. <i>Clinical Lung Cancer</i> , 2019, 20, e186-e194.	1.1	40
20	Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1035.	1.8	39
21	Next Generation Sequencing in Non-Small Cell Lung Cancer: New Avenues Toward the Personalized Medicine. <i>Current Drug Targets</i> , 2015, 16, 47-59.	1.0	38
22	<p>Antitumor activity of larotrectinib in tumors harboring NTRK &em>gene fusions: a short review on the current evidence</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 3171-3179.	1.0	38
23	Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2625.	1.8	38
24	Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGMâ„¢ Platform. <i>International Journal of Molecular Sciences</i> , 2015, 16, 28765-28782.	1.8	35
25	Safety and Efficacy of Nivolumab in Patients With Advanced Nonâ€‘small-cell Lung Cancer Treated Beyond Progression. <i>Clinical Lung Cancer</i> , 2019, 20, 178-185.e2.	1.1	35
26	The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 â‰¥ 50% advanced non-small-cell lung cancer. <i>ESMO Open</i> , 2021, 6, 100078.	2.0	35
27	Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition. <i>Targeted Oncology</i> , 2015, 10, 393-404.	1.7	34
28	Prognostic and predictive relevance of circulating tumor cells in patients with non-small-cell lung cancer. <i>Drug Discovery Today</i> , 2014, 19, 1671-1676.	3.2	33
29	Glyceraldehyde-3-phosphate dehydrogenase gene over expression correlates with poor prognosis in non small cell lung cancer patients. <i>Molecular Cancer</i> , 2013, 12, 97.	7.9	31
30	Role of microRNAs in malignant mesothelioma. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 2865-2878.	2.4	31
31	Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples. <i>BMC Cancer</i> , 2016, 16, 692.	1.1	27
32	Afatinib and Erlotinib in the treatment of squamous-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 2055-2062.	0.9	27
33	Downregulation of miR-99a/let-7c/miR-125b miRNA cluster predicts clinical outcome in patients with unresected malignant pleural mesothelioma. <i>Oncotarget</i> , 2017, 8, 68627-68640.	0.8	27
34	Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages Iâ€‘III Non-Small Cell Lung Cancer. <i>Disease Markers</i> , 2015, 2015, 1-18.	0.6	26
35	Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. <i>Journal of Clinical Medicine</i> , 2019, 8, 1566.	1.0	26
36	Pemetrexed for the treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1545-1558.	0.9	24

#	ARTICLE	IF	CITATIONS
37	The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1969-1976.	0.9	24
38	Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1351-1358.	2.0	24
39	Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. <i>European Journal of Cancer</i> , 2021, 150, 224-231.	1.3	24
40	Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2014, 10, 79-90.	1.1	23
41	Metabolic Parameters as Biomarkers of Response to Immunotherapy and Prognosis in Non-Small Cell Lung Cancer (NSCLC): A Real World Experience. <i>Cancers</i> , 2021, 13, 1634.	1.7	23
42	Oral vinorelbine in the treatment of non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1585-1599.	0.9	22
43	Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients. <i>Molecular Medicine</i> , 2019, 25, 15.	1.9	22
44	Exploring Response to Immunotherapy in Non-Small Cell Lung Cancer Using Delta-Radiomics. <i>Cancers</i> , 2022, 14, 350.	1.7	22
45	Afatinib for the treatment of advanced non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 889-903.	0.9	21
46	Clinical potential of necitumumab in non-small cell lung carcinoma. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 5427-5437.	1.0	21
47	Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 573-585.	1.0	21
48	Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 367-383.	1.0	21
49	Free drugs in clinical trials and their potential cost saving impact on the National Health Service: A retrospective cost analysis in Italy. <i>Lung Cancer</i> , 2013, 81, 236-240.	0.9	20
50	Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 939-948.	1.4	19
51	Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy. <i>British Journal of Cancer</i> , 2017, 116, 36-43.	2.9	18
52	CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 829-835.	1.4	17
53	The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab. <i>Cancers</i> , 2021, 13, 3117.	1.7	17
54	Potential application of cryobiopsy for histo-molecular characterization of mediastinal lymph nodes in patients with thoracic malignancies: a case presentation series and implications for future developments. <i>BMC Pulmonary Medicine</i> , 2022, 22, 5.	0.8	17

#	ARTICLE	IF	CITATIONS
55	Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview. <i>Future Oncology</i> , 2014, 10, 2081-2096.	1.1	16
56	Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma. <i>MicroRNA (Sharjah, United Arab Emirates)</i> , 2016, 5, 12-18.	0.6	15
57	Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer. <i>Clinical and Experimental Metastasis</i> , 2019, 36, 449-456.	1.7	15
58	EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study. <i>Journal of Thoracic Oncology</i> , 2018, 13, 228-236.	0.5	14
59	Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy. <i>Lung Cancer</i> , 2018, 117, 64-69.	0.9	13
60	Belagenpumatucel-L for the treatment of non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1371-1379.	1.4	12
61	Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR Mutation. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1711-1717.	0.5	12
62	Whole exome sequencing of independent lung adenocarcinoma, lung squamous cell carcinoma, and malignant peritoneal mesothelioma. <i>Medicine (United States)</i> , 2016, 95, e5447.	0.4	12
63	Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. <i>Immunotherapy</i> , 2019, 11, 873-879.	1.0	12
64	Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2015, 10, e50-e52.	0.5	11
65	Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in <sc>NSCLC</sc> cell lines poorly responsive to reversible <sc>EGFR</sc> tyrosine kinase inhibitors. <i>International Journal of Cancer</i> , 2015, 137, 2947-2958.	2.3	11
66	Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab. <i>Cancers</i> , 2019, 11, 125.	1.7	11
67	Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1007-1017.	1.4	10
68	The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1407-1412.	1.1	9
69	Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2016, 16, 1142-1154.	0.9	8
70	Hematopoietic growth factors in lung cancer. <i>Current Opinion in Oncology</i> , 2016, 28, 135-144.	1.1	7
71	Tumor microenvironment as a potential source of clinical biomarkers in non-small cell lung cancer: can we use enemy territory at our advantage?. <i>Journal of Thoracic Disease</i> , 2017, 9, 4300-4304.	0.6	7
72	Performance of the Oncomine™ Lung cfDNA Assay for Liquid Biopsy by NGS of NSCLC Patients in Routine Laboratory Practice. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 2895.	1.3	7

#	ARTICLE	IF	CITATIONS
73	New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 19-33.	0.9	6
74	Recent advances in squamous non-small cell lung cancer: evidence beyond predictive biomarkers. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1-4.	1.1	5
75	Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 551-561.	1.9	5
76	Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13668.	1.7	5
77	High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. <i>Journal of Hematology and Oncology</i> , 2022, 15, 9.	6.9	5
78	A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines. <i>Clinical Lung Cancer</i> , 2018, 19, 450-456.	1.1	4
79	An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an update. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 809-819.	0.9	4
80	Prospective Validation of the Italian Alliance Against Cancer Lung Panel in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, e637-e641.	1.1	4
81	Vinflunine for the treatment of non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1447-1455.	1.9	3
82	Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer. <i>Cancers</i> , 2019, 11, 441.	1.7	3
83	ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 679-686.	0.9	3
84	Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment. <i>Clinical and Translational Oncology</i> , 2020, 22, 1603-1610.	1.2	3
85	Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: focus on challenging populations. <i>Immunotherapy</i> , 2021, 13, 509-525.	1.0	3
86	Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib. <i>Clinical Pharmacology: Advances and Applications</i> , 2022, Volume 14, 1-9.	0.8	3
87	Radiation-Related Deregulation of TUBB3 and BRCA1/2 and Risk of Secondary Lung Cancer in Women With Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 21, 218-230.e6.	1.1	2
88	Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib. <i>Clinical Lung Cancer</i> , 2020, 21, e478-e487.	1.1	2
89	Evaluation of CTL antigen 4 (CTLA-4) expression as prognostic factor in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2011, 29, e21157-e21157.	0.8	2
90	Afatinib for the treatment of non-small cell lung cancer. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 1357-1364.	0.5	1

#	ARTICLE	IF	CITATIONS
91	Radiomic-based diagnostics in oncology: challenges toward clinical practice. <i>Oncoscience</i> , 2021, 8, 72-73.	0.9	1
92	Efficacy of motesanib diphosphate in non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1771-1780.	0.9	0
93	Looking for results in non-small-cell lung cancer: is bio-chemotherapy the right answer?. <i>Current Medical Research and Opinion</i> , 2014, 30, 2291-2293.	0.9	0
94	Cancer pathways analysis and correlation with survival in patients with advanced stage non-small cell lung cancer treated with PD-1 inhibitor.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21007-e21007.	0.8	0